Niagen Bioscience Q4 net sales rise

Reuters05:12
<a href="https://laohu8.com/S/NAGE">Niagen Bioscience</a> Q4 net sales rise

Overview

  • Bioscience company's Q4 net sales rose 16%, beating analyst expectations

  • Net income for Q4 declined due to higher operating expenses

  • Gross margin improved 160 bps to 64.1% in Q4

Outlook

  • Niagen Bioscience expects 2026 net sales to grow 10-15% year-over-year

  • Company anticipates slight improvement in gross margin for 2026

Result Drivers

  • TRU NIAGEN SALES - Q4 sales increased 21%, driven by e-commerce growth

  • GROSS MARGIN IMPROVEMENT - Improved 160 bps due to lower-cost inventory and better labor utilization

  • HIGHER OPERATING EXPENSES - Q4 net income affected by increased operating expenses, despite royalty settlement gains

Company press release: ID:nBw14YmWFa

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Sales

Beat

$33.8 mln

$31.70 mln (5 Analysts)

Q4 Net Income

$4.1 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Niagen Bioscience Inc is $14.00, about 187.5% above its March 3 closing price of $4.87

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 24 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment